Teva Pharmaceutical Industries Ltd. and Biolojic Design Ltd. have announced an exclusive license agreement to develop a potential novel antibody-based therapy for the treatment of atopic dermatitis and asthma.

The term cerebral small vessel disease (SVD) refers to the sum of all pathological processes affecting the small vessels of the brain. Although SVD has been recognized as a leading cause of age-related cognitive decline, its underlying mechanisms remain unknown. Moreover, therapeutic options for SVD patients are still limited, primarily because relevant disease models that can guide target identification and drug discovery are lacking.

Leishmaniasis is a vector-borne infectious disease caused by several protozoan Leishmania species with diverse clinical manifestations and limited treatment options to date. Researchers at Drugs for Neglected Diseases initiative have reported on the discovery and preclinical characterization of DNDI-6174, a novel inhibitor of the Leishmania cytochrome bc1 complex.

Researchers at Boston Children's Hospital and Harvard Medical School have explored the possibility of using anaplastic lymphoma kinase (ALK) as a target for the application of ALK.CAR T cells to treat neuroblastoma, the most common and deadliest tumor of infancy.

Encellin Inc. has announced the closing of a US$9.9 million financing round that will support the company’s development of its cell encapsulation platform with an initial focus on type 1 diabetes.